Document Detail

Effects of metoclopramide and metoclopramide/dopamine on blood pressure and insulin release in normotensive, hypertensive, and type 2 diabetic subjects.
MedLine Citation:
PMID:  20216207     Owner:  NLM     Status:  MEDLINE    
The objective is to determine cardiovascular and insulin release effects under metoclopramide (MTC) and dopamine (DA) infusion by using an acute comparative design with the intravenous infusion of both drugs. We evaluated 15 normal (normotensive and normoglycemic) subjects, 13 hypertensive, and 15 type 2 diabetic subjects. Subjects were submitted to an experimental design in which we first gave them a 0.9% saline solution for 30 minutes, and then administered MTC at 7.5 microg kg min through an intravenous infusion during a period of 30 minutes. Although subjects were receiving MTC, we added an intravenous infusion of DA at 1-3 microg kg min during 30 minutes. Blood pressure, heart rate, serum lipid profile, and insulin levels were measured. Sympathetic reactivity by the cold pressor test was also measured. In normotensive subjects, there was a systolic blood pressure and heart rate increase during MTC plus DA infusion. In subjects with diabetes mellitus there was a heart rate increase without changes in blood pressure during the MTC plus DA infusion period. In hypertensive subjects, MTC induced a significant decrease of systolic and diastolic blood pressure. During MTC plus DA period there was an increase of heart rate but no significant changes in blood pressure. During cold pressor test in both diabetic and hypertensive subjects, there were significant increases of both blood pressure and heart rate. Insulin serum levels increased in normotensive and hypertensive subjects but were attenuated in subjects with diabetes mellitus. We conclude that there is a pharmacologic interaction between MTC and DA, that the pressor effects of DA are due to activation to beta and alpha adrenergic receptors, and that the cardiovascular effects of DA in type 2 diabetic subjects are attenuated by a probable defect in sympathetic system and to endothelial dysfunction.
Freddy Contreras; Christian Fouillioux; Mary Lares; Hector Bolívar; Rafael Hernández Hernández; Manuel Velasco; Raquel Cano; Maricarmen Chacin; Valmore Bermúdez
Related Documents :
10450117 - The international database of self-recorded blood pressures in normotensive and untreat...
21624057 - Raloxifene reduces blood pressure in hypertensive animals after ovarian hormone depriva...
18292757 - Target organ damage in "white coat hypertension" and "masked hypertension".
21586307 - Local transdermal delivery of phenylephrine to the anal sphincter muscle using micronee...
8005267 - Ivox in ards: respiratory effects and serious complications.
12409247 - Photodegradation of 1-nitropyrene in solution and in the adsorbed state.
Publication Detail:
Type:  Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of therapeutics     Volume:  17     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2010 May-Jun
Date Detail:
Created Date:  2010-05-18     Completed Date:  2010-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  320-4     Citation Subset:  IM    
Clinical Pharmacology Unit, Vargas Medical School, Central University of Venezuela, Caracas, Venezuela.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects*
Cold Temperature / diagnostic use
Diabetes Mellitus, Type 2 / physiopathology
Dopamine / pharmacology*
Dopamine Agents / pharmacology
Dopamine Antagonists / pharmacology
Drug Interactions
Endothelium, Vascular / physiopathology
Heart Rate / drug effects
Hypertension / physiopathology
Infusions, Intravenous
Insulin / metabolism*
Lipids / blood
Metoclopramide / pharmacology*
Middle Aged
Receptors, Adrenergic, alpha / drug effects,  metabolism
Receptors, Adrenergic, beta / drug effects,  metabolism
Reg. No./Substance:
0/Dopamine Agents; 0/Dopamine Antagonists; 0/Lipids; 0/Receptors, Adrenergic, alpha; 0/Receptors, Adrenergic, beta; 11061-68-0/Insulin; 364-62-5/Metoclopramide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Haemodynamical Variables Versus Endothelial Hormones in Hypertensive and Type 2 Diabetic Patients Wi...
Next Document:  PPAR-gamma Agonists and Their Role in Type 2 Diabetes Mellitus Management.